Pearson T C, Madsen J C, Larsen C P, Morris P J, Wood K J
Nuffield Department of Surgery, University of Oxford John Radcliffe Hospital, Headington, England.
Transplantation. 1992 Sep;54(3):475-83. doi: 10.1097/00007890-199209000-00018.
The T-cell-mediated immune response usually results in the rapid destruction of organ allografts transplanted between murine strains incompatible for major and minor histocompatibility antigens. This response may be modified by pretreatment with either donor-specific antigen or anti-CD4 monoclonal antibody. Previous work by others has shown that combined treatment of mice with soluble protein antigens and anti-CD4 monoclonal antibody can produce antigen-specific B cell unresponsiveness that continues long after the nonspecific immunosuppressive effect of the mAb treatment has resolved. Following this principle we have shown that adult C3H/He mice can be made specifically unresponsive to vascularized C57BL/10 cardiac allografts by pretreating the recipient with donor alloantigen under the cover of a brief course of mAb against CD4. A full-dose response analysis shows that the dose of mAb is critically important for the successful induction of tolerance. Tolerance induction using this protocol is dependent on treatment with donor major histocompatibility complex antigens and occurs in the presence of marked depletion but not complete elimination of the CD4+ T cell subset. The unresponsiveness to alloantigen is antigen specific, as determined by the ineffectiveness of third-party (C57BL/10) alloantigen when combined with anti-CD4 mAb to induce long-term survival of BALB/c allografts in C3H/He recipients. The tolerant state is specific and effective in the long-term as indicated by the specific acceptance of C57BL/10 skin grafts in recipients with surviving C57BL/10 cardiac allografts. This study provides a simple method for the successful induction of specific transplantation tolerance in the adult across a full H-2 major and minor antigen mismatch strain combination. The results illustrate the important role of the CD4 molecule in the T cell response to alloantigen in vivo and suggest possibilities for the therapeutic manipulation of complex immune reactions.
T细胞介导的免疫反应通常会导致在主要和次要组织相容性抗原不相容的小鼠品系之间移植的器官同种异体移植物迅速被破坏。这种反应可通过用供体特异性抗原或抗CD4单克隆抗体进行预处理来改变。其他人先前的研究表明,用可溶性蛋白抗原和抗CD4单克隆抗体联合处理小鼠可产生抗原特异性B细胞无反应性,这种无反应性在单克隆抗体治疗的非特异性免疫抑制作用消退后仍会持续很长时间。遵循这一原则,我们已经表明,通过在针对CD4的单克隆抗体的短期疗程掩护下用供体同种异体抗原预处理受体,可以使成年C3H/He小鼠对血管化的C57BL/10心脏同种异体移植物产生特异性无反应性。全剂量反应分析表明,单克隆抗体的剂量对于成功诱导耐受性至关重要。使用该方案诱导耐受性取决于用供体主要组织相容性复合体抗原进行治疗,并且发生在CD4+T细胞亚群明显耗竭但未完全消除的情况下。对同种异体抗原的无反应性是抗原特异性的,这是通过第三方(C57BL/10)同种异体抗原与抗CD4单克隆抗体联合使用时不能诱导C3H/He受体中BALB/c同种异体移植物长期存活来确定的。耐受状态在长期内是特异性且有效的,这通过在存活有C57BL/10心脏同种异体移植物的受体中特异性接受C57BL/10皮肤移植物来表明。这项研究提供了一种简单的方法,可成功诱导成年个体对完整的H-2主要和次要抗原错配品系组合产生特异性移植耐受性。结果说明了CD4分子在体内T细胞对同种异体抗原反应中的重要作用,并提出了治疗性操纵复杂免疫反应的可能性。